Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.

Christoph Zielinski; István Láng; Moshe Inbar; Zsuzsanna Kahán; Richard Greil; Semir Beslija; Salomon M Stemmer; Zanete Zvirbule; Günther G Steger; Bohuslav Melichar; Tadeusz Pienkowski; Daniela Sirbu; Luboš Petruzelka; Alexandru Eniu; Bella Nisenbaum; Magdalena Dank; Rodica Anghel; Diethelm Messinger; Thomas Brodowicz

doi:10.1016/S1470-2045(16)30154-1

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.

Christoph Zielinski, István Láng, Moshe Inbar, Zsuzsanna Kahán, Richard Greil (Co-author), Semir Beslija, Salomon M Stemmer, Zanete Zvirbule, Günther G Steger, Bohuslav Melichar, Tadeusz Pienkowski, Daniela Sirbu, Luboš Petruzelka, Alexandru Eniu, Bella Nisenbaum, Magdalena Dank, Rodica Anghel, Diethelm Messinger, Thomas Brodowicz

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Original Article (Journal) › peer-review

48 Citations (Web of Science)

Original language	English
Pages (from-to)	1230-1239
Journal	LANCET ONCOL
Volume	17
Issue number	9
DOIs	https://doi.org/10.1016/S1470-2045(16)30154-1
Publication status	Published - 2016

Keywords

CHEMOTHERAPY
SURVIVAL
THERAPY
WEIGHT

Access to Document

10.1016/S1470-2045(16)30154-1

Cite this

Zielinski, C., Láng, I., Inbar, M., Kahán, Z., Greil, R., Beslija, S., Stemmer, S. M., Zvirbule, Z., Steger, G. G., Melichar, B., Pienkowski, T., Sirbu, D., Petruzelka, L., Eniu, A., Nisenbaum, B., Dank, M., Anghel, R., Messinger, D., & Brodowicz, T. (2016). Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial. LANCET ONCOL, 17(9), 1230-1239. https://doi.org/10.1016/S1470-2045(16)30154-1

@article{bf640381c8b1495a878fb7543ab479b3,

title = "Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.",

keywords = "CHEMOTHERAPY, SURVIVAL, THERAPY, WEIGHT",

author = "Christoph Zielinski and Istv{\'a}n L{\'a}ng and Moshe Inbar and Zsuzsanna Kah{\'a}n and Richard Greil and Semir Beslija and Stemmer, {Salomon M} and Zanete Zvirbule and Steger, {G{\"u}nther G} and Bohuslav Melichar and Tadeusz Pienkowski and Daniela Sirbu and Lubo{\v s} Petruzelka and Alexandru Eniu and Bella Nisenbaum and Magdalena Dank and Rodica Anghel and Diethelm Messinger and Thomas Brodowicz",

note = "Greil: IIIrd Medical Department with Hematology and Medical Oncology, Paracelsus Medical University, Salzburg, Austria",

year = "2016",

doi = "10.1016/S1470-2045(16)30154-1",

language = "English",

volume = "17",

pages = "1230--1239",

journal = "LANCET ONCOL",

issn = "1470-2045",

publisher = "Elsevier ",

number = "9",

}

Zielinski, C, Láng, I, Inbar, M, Kahán, Z, Greil, R, Beslija, S, Stemmer, SM, Zvirbule, Z, Steger, GG, Melichar, B, Pienkowski, T, Sirbu, D, Petruzelka, L, Eniu, A, Nisenbaum, B, Dank, M, Anghel, R, Messinger, D & Brodowicz, T 2016, 'Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.', LANCET ONCOL, vol. 17, no. 9, pp. 1230-1239. https://doi.org/10.1016/S1470-2045(16)30154-1

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial. / Zielinski, Christoph; Láng, István; Inbar, Moshe et al.
In: LANCET ONCOL, Vol. 17, No. 9, 2016, p. 1230-1239.

Research output: Contribution to journal › Original Article (Journal) › peer-review

TY - JOUR

T1 - Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.

AU - Zielinski, Christoph

AU - Láng, István

AU - Inbar, Moshe

AU - Kahán, Zsuzsanna

AU - Greil, Richard

AU - Beslija, Semir

AU - Stemmer, Salomon M

AU - Zvirbule, Zanete

AU - Steger, Günther G

AU - Melichar, Bohuslav

AU - Pienkowski, Tadeusz

AU - Sirbu, Daniela

AU - Petruzelka, Luboš

AU - Eniu, Alexandru

AU - Nisenbaum, Bella

AU - Dank, Magdalena

AU - Anghel, Rodica

AU - Messinger, Diethelm

AU - Brodowicz, Thomas

N1 - Greil: IIIrd Medical Department with Hematology and Medical Oncology, Paracelsus Medical University, Salzburg, Austria

PY - 2016

Y1 - 2016

KW - CHEMOTHERAPY

KW - SURVIVAL

KW - THERAPY

KW - WEIGHT

U2 - 10.1016/S1470-2045(16)30154-1

DO - 10.1016/S1470-2045(16)30154-1

M3 - Original Article (Journal)

C2 - 27501767

SN - 1470-2045

VL - 17

SP - 1230

EP - 1239

JO - LANCET ONCOL

JF - LANCET ONCOL

IS - 9

ER -